These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 37374164)

  • 1. Advances in Molecular Profiling and Their Potential Influence on the Extent of Surgery in Well-Differentiated Thyroid Carcinoma (WDTC).
    Parpounas C; Constantinides V
    Life (Basel); 2023 Jun; 13(6):. PubMed ID: 37374164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
    Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
    Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational analysis using next generation sequencing in pediatric thyroid cancer reveals BRAF and fusion oncogenes are common.
    Newfield RS; Jiang W; Sugganth DX; Hantash FM; Lee E; Newbury RO
    Int J Pediatr Otorhinolaryngol; 2022 Jun; 157():111121. PubMed ID: 35397361
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Camargo Barros-Filho M; Barreto Menezes de Lima L; Bisarro Dos Reis M; Bette Homem de Mello J; Moraes Beltrami C; Lopes Pinto CA; Kowalski LP; Rogatto SR
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Profile of Locally Aggressive Well Differentiated Thyroid Cancers.
    Mady LJ; Grimes MC; Khan NI; Rao RH; Chiosea SI; Yip L; Ferris RL; Nikiforov YE; Carty SE; Duvvuri U
    Sci Rep; 2020 May; 10(1):8031. PubMed ID: 32415114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational Analysis in Pediatric Thyroid Cancer and Correlations with Age, Ethnicity, and Clinical Presentation.
    Nikita ME; Jiang W; Cheng SM; Hantash FM; McPhaul MJ; Newbury RO; Phillips SA; Reitz RE; Waldman FM; Newfield RS
    Thyroid; 2016 Feb; 26(2):227-34. PubMed ID: 26649796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Coexistent BRAF
    Moon S; Song YS; Kim YA; Lim JA; Cho SW; Moon JH; Hahn S; Park DJ; Park YJ
    Thyroid; 2017 May; 27(5):651-660. PubMed ID: 28181854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late-onset distant metastases confer poor prognosis in patients with well-differentiated thyroid cancer.
    Jung CK; Lee S; Bae JS; Lim DJ
    Gland Surg; 2020 Oct; 9(5):1857-1866. PubMed ID: 33224861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer: Genetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer Mortality.
    Liu R; Bishop J; Zhu G; Zhang T; Ladenson PW; Xing M
    JAMA Oncol; 2017 Feb; 3(2):202-208. PubMed ID: 27581851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How limited molecular testing can also offer diagnostic and prognostic evaluation of thyroid nodules processed with liquid-based cytology: Role of TERT promoter and BRAF V600E mutation analysis.
    Dell'Aquila M; Fiorentino V; Martini M; Capodimonti S; Cenci T; Lombardi CP; Raffaelli M; Pontecorvi A; Fadda G; Pantanowitz L; Larocca LM; Rossi ED
    Cancer Cytopathol; 2021 Oct; 129(10):819-829. PubMed ID: 34076961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.
    Jin L; Chen E; Dong S; Cai Y; Zhang X; Zhou Y; Zeng R; Yang F; Pan C; Liu Y; Wu W; Xing M; Zhang X; Wang O
    Oncotarget; 2016 Apr; 7(14):18346-55. PubMed ID: 26943032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approach to risk stratification for papillary thyroid carcinoma based on molecular profiling: institutional analysis.
    Staubitz JI; Müller C; Heymans A; Merten C; Roos B; Poplawski A; Ludt A; Strobl S; Springer E; Schad A; Roth W; Musholt TJ; Hartmann N
    BJS Open; 2023 May; 7(3):. PubMed ID: 37146205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations of the
    Liu R; Li Y; Chen W; Cong J; Zhang Z; Ma L; Chu L; Xiao H; Zhang Y; Liu Y; Xu Y; Yu Q; Yang X; Sun C
    Oncol Lett; 2020 Oct; 20(4):50. PubMed ID: 32802170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mutations as a possible factor for determining extent of thyroid surgery.
    Krasner JR; Alyouha N; Pusztaszeri M; Forest VI; Hier MP; Avior G; Payne RJ
    J Otolaryngol Head Neck Surg; 2019 Oct; 48(1):51. PubMed ID: 31623671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
    Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
    Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management and outcome of recurrent well-differentiated thyroid carcinoma.
    Palme CE; Waseem Z; Raza SN; Eski S; Walfish P; Freeman JL
    Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):819-24. PubMed ID: 15262757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic characterization of high-recurrence risk papillary thyroid carcinoma in a southern Chinese population.
    Li M; Jia H; Qian Q; Wen P; Chen C; Hua Y; Wang K; Zhang W; Shi F
    Diagn Pathol; 2020 May; 15(1):49. PubMed ID: 32393293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-existence of
    Ren H; Shen Y; Hu D; He W; Zhou J; Cao Y; Mao Y; Dou Y; Xiong W; Xiao Q; Zhang Y; Su X
    Cancer Manag Res; 2018; 10():1005-1013. PubMed ID: 29760568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
    Liu X; Qu S; Liu R; Sheng C; Shi X; Zhu G; Murugan AK; Guan H; Yu H; Wang Y; Sun H; Shan Z; Teng W; Xing M
    J Clin Endocrinol Metab; 2014 Jun; 99(6):E1130-6. PubMed ID: 24617711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.